Skip to content
10-Q

Quarterly Report

enGene Therapeutics Inc. ENGN ENGNW

0001193125-26-097541

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Mar 3, 2026 66.99M sh
Shares Diluted Q1 2026 · Jan 31, 2026 67.26M sh
Shares Diluted Q1 2026 · Jan 31, 2025 50.98M sh
Capex Q1 2026 · Jan 31, 2026 $153K
Capex Q1 2026 · Jan 31, 2025 $299K
Operating Cash Flow Q1 2026 · Jan 31, 2026 −$28.9M
Operating Cash Flow Q1 2026 · Jan 31, 2025 −$25.7M
Cash And Equivalents Q1 2026 · Jan 31, 2026 $36.61M
Cash And Equivalents Q1 2026 · Oct 31, 2025 $50.15M
Stockholders Equity Q1 2026 · Jan 31, 2026 $281.55M
Stockholders Equity Q1 2026 · Oct 31, 2025 $167.71M
Stockholders Equity Q1 2026 · Jan 31, 2025 $249.95M
Stockholders Equity Q1 2026 · Oct 31, 2024 $272.61M
Current Liabilities Q1 2026 · Jan 31, 2026 $24.61M
Current Liabilities Q1 2026 · Oct 31, 2025 $31.98M
Total Liabilities Q1 2026 · Jan 31, 2026 $55.57M
Total Liabilities Q1 2026 · Oct 31, 2025 $53.76M
Current Assets Q1 2026 · Jan 31, 2026 $289.22M
Current Assets Q1 2026 · Oct 31, 2025 $201.39M
Total Assets Q1 2026 · Jan 31, 2026 $337.11M
Total Assets Q1 2026 · Oct 31, 2025 $221.47M
Eps Diluted Q1 2026 · Jan 31, 2026 $0.44
Eps Diluted Q1 2026 · Jan 31, 2025 $0.48
Eps Basic Q1 2026 · Jan 31, 2026 $0.44
Eps Basic Q1 2026 · Jan 31, 2025 $0.48
Sga Expense Q1 2026 · Jan 31, 2026 $8.93M
Sga Expense Q1 2026 · Jan 31, 2025 $6.64M
Rd Expense Q1 2026 · Jan 31, 2026 $22.26M
Rd Expense Q1 2026 · Jan 31, 2025 $19.97M
Net Income Q1 2026 · Jan 31, 2026 −$29.75M
Net Income Q1 2026 · Jan 31, 2025 −$24.62M
Operating Income Q1 2026 · Jan 31, 2026 −$31.19M
Operating Income Q1 2026 · Jan 31, 2025 −$26.61M